Tag Archives: management

A Volatile, Illiquid Paradise

Summary Two characteristics of today’s market – volatility and illiquidity – are in focus for many investors. What many small investors fail to realize is that straightforward Graham-style investing isn’t the only way to profit from volatility. This market is paradise for the small, self-directed value investor with a willingness to take on insurance liabilities. There is a lot of confusion about volatility . Some people think that volatility is the square root of the variance in a price series. They would be correct, except when they’re not. Others think that volatility is whatever the CBOE’s VIX metric says. This is also true, but limiting. Similarly, still others would argue that volatility is whatever the derivatives market implies that volatility is. Most will agree, however, that volatility is bad . We say “most,” but Seeking Alpha really isn’t “most” people. Any investor with even a cursory understanding of Graham-style investing knows the metaphor of Mr. Market, the moody, irrational purveyor of market prices. If we are patient with him, we can take advantage of his irrationality, which is what we ought to do as investors. In this understanding, volatility is simply noise , and it certainly isn’t a bad thing. As value-driven investors, we encourage this latter mentality, but we wonder if “volatility-as-noise” cuts the conversation too short. We see more opportunity here than the traditional Graham paradigm suggests. Taking advantage of more When we take advantage of what we estimate to be mispriced securities, we are directly using the volatility of the market to our advantage. The idea is that our counterparties (sellers or buyers) are simply lacking in time, cash, or information (or perhaps they are limited by fiduciary obligations), and when we trade shares, their loss is our gain. What if we take this one step further? If we are comfortable taking advantage of others’ value miscalculations by buying or selling a stock at a certain price, why would we not also be comfortable taking advantage of our counterparties’ miscalculations (or irrational obsession) with volatility itself? Return to the popular impressions of volatility. Each has profound limitations. When we take the square root of a variance , we are more often than not simply using a security’s end-of-day closing prices. This ignores daily ranges, which can be quite significant. When we refer only to the VIX , we correlate volatility almost exclusively with indices’ downside and thereby mistake “volatility” for “fear” (thank the financial media for this). When we rely on the implied volatility of derivatives, we assume a standard deviation of returns in a stock, largely ignoring the possibility of gapping and skewed returns. Assessing risk with any one of these volatility measures is a fool’s errand — and there are plenty of fools in the market. The illiquidity trap When we view volatility as baseless noise rather than risk , a whole world of opportunity presents itself. I.e., if we think that Mr. Market’s irrationality presents us with opportunity, then others’ “risk” can be our reward. If you were afraid of volatility (here meaning simply variation in a price series), as many portfolio managers are (think pensions), you would be eager to hedge against it. This has always been the case, though as we gaze into the maw of a potential bear market, survival instinct makes portfolio insurance more appealing than ever. As a corollary, selling insurance (puts) in periods of (VIX-style) volatility can be quite profitable. August 24th demonstrated, however, that this is not “normal” volatility. In the last few years, the Wild West of HFT penny-spread market-making turned the average transaction size into a tiny fraction of what it used to be, and largely pushed other market-makers out of the game. When the exchanges then gradually disincentivized even HFT market-making (thank you Michael Lewis ), no one was left to provide liquidity — especially in times of uncertainty (see 2010 Flash Crash ). What this means for the aforementioned portfolio managers is that the exchanges are not friendly places to do business in volume. For large orders, crossing networks and dark pools are preferred. The problem with these venues is that your counterparty is typically as well-informed as you are (i.e., they won’t be buyers when things are hairy). With nobody to sell to, paying a premium for a put option (and guaranteeing yourself a customer at a pre-determined price) becomes even more appealing. Selling insurance Value investors have beliefs about the intrinsic value of companies . Whether by virtue of cash-flow growth, “real options,” management savvy, or relative undervaluation, we can determine a range of prices at which we would be happy to own any publicly traded stock. Sometimes those ranges are small and confident; sometimes they are wide and uncertain; sometimes they converge at $0.00. Regardless, we have a basis for investment and a preferred entry point. The upshot to this assumption is that by selling insurance to portfolio managers in the form of put options, we can have our cake and eat it too. By selling a put at a strike price within our target range, we can not only provide ourselves the opportunity to buy into a stock at a favorable price, but also collect premium for our trouble (regardless). Furthermore, since brokers tend to be generous in their risk calculations for put-sellers (thank the Black-Scholes-Merton equation for conventional risk-assessment), we can get our fingers into all sorts of opportunities at relatively low cost, spread risk across multiple sectors, and collect premium while we wait. To most speculators, “risk of assignment” in the case of a decline in price would be detrimental. To a value investor, “risk of assignment” at a favorable price doesn’t sound much like risk at all. This is the strength of being a value-oriented investor. Ignoring a high-volatility, high-premium market environment is a missed opportunity. To some readers, this will already seem mind-numbingly obvious. Indeed, some contributors on Seeking Alpha are already practitioners of this philosophy (though they are not usually the most visible). Others, however, may not have seen an opportunity for this approach in the frothier, low-implied-volatility markets of the past few years, and may have discarded the idea out of hand. Now – in a high-volatility, high-uncertainty, and low-liquidity market – is the time to reconsider.

Think Flexible With Emerging-Market Asset Classes

By Morgan Harting A midyear sell-off in emerging-market stocks highlighted the challenges investors face in volatile times. We think a flexible approach that spans the asset classes can help. Equities dropped by about 25% between April and August, and volatility spiked to levels not seen since the mid-2013 “taper tantrum.” The cause: investors fretted about slowing Chinese growth, weaker commodity prices and looming US Federal Reserve rate hikes. It was particularly tough for passive equity investors whose exposure was concentrated in the BRIC countries – Brazil, Russia, India and China. Don’t Pay for Beta in Emerging Markets This experience seemed to reinforce the notion that investors shouldn’t “pay for beta,” particularly in emerging markets. Passive equity strategies in that arena can be as much as 50% more volatile than in developed markets. The added return needed to justify a passive equity allocation requires a lot of conviction – or disregard for higher volatility. The good news is that emerging markets are still pretty inefficient. Active managers can add value by generating higher returns to justify higher risk, or by reducing the risk in passive strategies. We think the flexibility to tap multiple asset classes in one portfolio – including bonds – can be effective. It’s a compelling way to get more active, seeking to dampen volatility and improve risk-adjusted returns. Episodes like the taper tantrum – a global sell-off across asset classes – can disrupt things. But we think those are the exception, not the rule, in cross-asset diversification. In the recent downturn, multi-asset strategies did indeed outperform passive broad-market equity strategies. Multi-Asset: Newer to Emerging Markets Developed-market multi-asset strategies have been around for a while, but the emerging-market versions are relative newcomers. Many investors still prefer asset-class “pure” emerging-market strategies: all equity or all debt. As the thinking goes, it’s better for managers to focus on asset-class expertise than venture into other areas. We think high volatility in passive emerging-market equity changes the argument. Investors should use every tool to reduce risk and preserve returns. Multi-asset emerging-market approaches offer a tool that controls volatility better than just moving to lower-volatility stocks. The average volatility of emerging-market stocks? It’s 22% over the past decade. For bonds, it’s less than 5%, and with much less downside risk. The recent sell-off in emerging markets has made the volatility and downside risk-reduction benefits more evident, as these managers have outperformed meaningfully. The Case for Crossing Asset-Class Boundaries Granted, some active managers are very skilled in individual asset classes. But no matter which emerging-market asset class you’re in, the main return driver is broad emerging-market risk. The proof is in the return patterns. Over the past decade, the correlation between emerging-market stocks and bonds has been 0.7, much higher than the 0.1 between developed-market equity and debt. 1 With so many common return drivers among emerging asset classes, it seems to make more sense to manage emerging-market equity and debt together in a single portfolio than it does with developed markets. After all, the correlation between US and Japanese stocks is just 0.5, 2 but it’s hardly controversial anymore to suggest one manager for a global equity portfolio. Many investors want to take part in emerging-market growth and may see today’s attractive valuations as an enticing entry point. But they also might question whether it’s really worth it after factoring risk into the equation. We think multi-asset approaches offer a way to reduce some of that risk. Morgan C. Harting, CFA, CAIA Portfolio Manager – Multi-Asset Solutions 1,2 For the 10-year period ending September 25, 2015. Emerging-market stocks represented by the MSCI Emerging Markets Index; emerging-market bonds by the J.P. Morgan EMBI Global; US and Japanese stocks by their respective MSCI indices. Disclaimer: MSCI makes no express or implied warranties or representations, and shall have no liability whatsoever with respect to any MSCI data contained herein. The views expressed herein do not constitute research, investment advice or trade recommendations and do not necessarily represent the views of all AB portfolio-management teams.

Biotech ETFs Looking Attractive After Sell-Off

The biotech sector has long been the investors’ darling and the stocks saw an enormous run from late 2011 till this past summer, rising 340%. But the recent global market rout took away the sheen away from the sector, which faced a double whammy when Democratic Presidential candidate Hillary Clinton tweeted on drug price limits and increased regulatory scrutiny. The tweet led to a brutal seven-day sell-off, sending the Nasdaq Biotechnology index into a deep bear territory with a decline of more than 25% from its July highs. With this, the index wiped out all of its gain made this year. While investors may want to consider staying on the sidelines for the time being given the bearish trend, risk tolerant long-term investors could consider this slump a buying opportunity, should they have the patience for extreme volatility. Reasons to Buy Despite the current slide, the outlook for the sector is quite promising. This is especially true as the biotech sector is still clearly outpacing the broad market index from the year-to-date look. In fact, the sector enjoyed a strong rally over the past five years, gaining nearly 250% versus the gain of 64.8% for the S&P 500 index. This trend is likely to continue thanks to promising drug launches, cost-cutting efforts, an aging population, ever-increasing demand for new drugs, ever-increasing healthcare spending, a merger & acquisition frenzy, expansion into emerging markets and the Affordable Care Act or Obamacare. Additionally, biotech stocks provide a defensive tilt to the portfolio amid political or economic turmoil. Further, most of the stocks have sold off sharply, making their valuations immense attractive at the current levels (read: The 3 Key Factors in Biotech ETF Investing ). Given the promising long-term trends and the sector’s high growth potential, biotech stocks are due for a rebound and will likely move higher this fall. While individual stock investing is certainly an option, a look at the top ranked biotech ETFs could be a lesser risky way to tap the same broad trends. Top ETF Choices We have found a number of ETFs that have the top Zacks ETF Rank of 2 or ‘Buy’ rating in the space and that are expected to outperform in the months to come. These have gained the most from the sector’s surge in yesterday’s trading session and thus have superior weighting methodologies, which could allow them to continue leading the biotech space higher (read: all the Top Ranked ETFs ). ALPS Medical Breakthroughs ETF (NYSEARCA: SBIO ) This fund targets companies with one or more drugs in Phase II or Phase III FDA clinical trials by tracking the Poliwogg Medical Breakthroughs Index. It is a small cap centric fund, having amassed $143.2 million in its asset base since its debut late last December. The product holds 82 stocks in its basket with a well-diversified portfolio as none of the security holds more than 4.89% of assets. The product charges 50 bps in fees per year from investors and trades in good average daily volume of around 143,000 shares. It gained 5.2% in yesterday’s trading session and nearly 7% in the year-to-date timeframe. iShares Nasdaq Biotechnology ETF (NASDAQ: IBB ) This fund provides exposure to 144 firms by tracking the Nasdaq Biotechnology Index and charging 48 bps in annual fees. With AUM of nearly $7.5 billion and average daily volume of about 2.1 million shares, this is the largest and the most popular ETF in the biotech space. The product is slightly concentrated on the top five firms, which makes up for at least 8% share each. Other firms hold less than 4.10% of total assets. IBB gained 4.8% in yesterday’s trading session and is down 4.6% in the year-to-date time frame. SPDR Biotech ETF (NYSEARCA: XBI ) With AUM of $2 billion and average daily volume of 4.2 million shares, XBI is extremely liquid and an easily traded fund. It provides equal weight exposure across of around 1% to 103 stocks by tracking the S&P Biotechnology Select Industry Index. This suggests that the product has no concentration issue and offers huge diversification benefits. The product has a definite tilt toward small cap securities, as mid and large caps account for around 10% each. It charges a relatively low fee of 35 bps a year for the exposure. The ETF added 3.7% yesterday and is down 3.1% so far this year. BioShares Biotechnology Products ETF (NASDAQ: BBP ) This ETF follows the LifeSci Biotechnology Products Index, which measures the performance of biotechnology companies with a primary product offering that has received the U.S. Food and Drug Administration approval. Holding 38 stocks, the product has moderate concentration across components with each holding less than 5.5% share. Small caps dominate with 60%, followed by 25% in large caps and the rest in mid caps. The product has accumulated AUM of about $21.7 million since its debut last December and charges 85 bps in fees per year. Volume is light trading under 27,000 shares a day. BBP rose 3.5% yesterday and has returned about 2% in the year-to-date timeframe. Link to the original post on Zacks.com